CRISPR-based technologies for the manipulation of eukaryotic genomes

By Alexis C. Komor, A. Badran, David R. Liu. 2016

992 citations recorded by the source corpus.

The CRISPR-Cas9 RNA-guided DNA endonuclease has contributed to an explosion of advances in the life sciences that have grown from the ability to edit genomes within living cells. In this review we summarize CRISPR-based technologies that enable mammalian genome editing and their various applications. We describe recent developments that extend the generality, DNA specificity, product selectivity, and fundamental capabilities of natural CRISPR systems, and some of the remarkable advancements in basic research, biotechnology, and therapeutics development that these developments have facilitated.

Subfields: Business and International Management, Molecular Biology

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

Evolved Cas9 variants with broad PAM compatibility and high DNA specificity (2018, neutral): “2a and Extended Data Figs 4, 5a–5d, 6) versus genomic targets (Fig.”
Evaluation and Minimization of Cas9-Independent Off-Target DNA Editing by Cytosine Base Editors (2020, neutral): “Cytosine base editors (CBEs) are genome editing agents consisting of a cytidine deaminase fused to a catalytically impaired Cas9 protein and one or more copies of a uracil glycosylase inhibitor (UGI) 1,2 .”
The Biology of CRISPR-Cas: Backward and Forward. (2018, positive): “The efﬁciency and simplicity of CRISPR-Cas9 and other select interference mechanisms has been leveraged in powerful genome editing tools (Komor et al., 2017).”
Genome Engineering Using the CRISPR Cas9 System (2019, background): “Those indels have become a serious issue due to their participation in gene disruption, splicing stage and regulatory sequences for different application in which indels are unwanted or not desired [19].”
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. (2019, neutral): “126 ,127 The barriers to broad clinical translation of CRISPR-Cas systems include (1) imperfect DNA-targeting speci ﬁ city leading to off-target effects, 128 (2) low ef ﬁ ciency of genome editing using HDR, 129 and (3) challenging delivery of CRISPR-Cas components.”